



Extravascular inflammation does not increase atherosclerosis in apoE-deficient mice

Kerry W.S. Ko^{b,1}, David B. Corry^{a,c}, Cory F. Brayton^d, Antoni Paul^{a,2}, Lawrence Chan^{a,b,*}

^a Department of Medicine, Baylor College of Medicine, Houston, TX, USA

^b Department of Molecular & Cellular Biology, Baylor College of Medicine, Houston, TX, USA

^c Department of Immunology, Baylor College of Medicine, Houston, TX, USA

^d Center for Comparative Medicine, Baylor College of Medicine, Houston, TX, USA

ARTICLE INFO

Article history:

Received 14 April 2009

Available online 22 April 2009

Keywords:

Inflammation
Atherosclerosis
Dermatitis
Lung disease
Peritonitis

ABSTRACT

There is much speculation whether extravascular inflammation accelerates atherosclerosis. We tested this hypothesis in apoE^{-/-} mice using three well-characterized models of non-autoimmune chronic inflammation: croton oil-induced skin inflammation, *Aspergillus fumigatus* antigen-induced allergic lung disease, and *A. fumigatus* antigen-induced peritonitis. The croton oil model produced recurrent inflammatory skin ulceration, and marked increases in plasma levels of IL-6 and serum amyloid A (SAA). The allergic lung disease model showed strong local inflammation with eosinophilic infiltration and serum IgE induction. The recurrent peritonitis model was accompanied by mild elevation in plasma SAA levels. Aortic atherosclerosis was quantified by computer-assisted morphometry of *en face* arteries in apoE^{-/-} mice at 34 weeks for the croton oil model, 26 and 42 weeks for the allergic lung disease model, and 26 weeks for the peritonitis model. We found that all three forms of chronic extravascular inflammation had no effect on the rate of atherosclerosis development.

© 2009 Elsevier Inc. All rights reserved.

Introduction

Atherosclerosis is the commonest underlying pathology of most cardiovascular diseases (CVD), the major cause of mortality and morbidity in developed countries [1]. Dyslipidemia is a dominant risk factor in atherosclerosis development [2]. There is increasing evidence, however, that inflammation mediates many of the ill effects of dyslipidemia [3]. Furthermore, atherosclerotic lesions are themselves loci of inflammation and a source of pro-inflammatory cytokines [4].

We speculated that extravascular inflammatory processes, by diverse mechanisms, including leukocyte activation, immunomodulation, and increased circulating inflammatory mediators, could modulate the inflammatory response in lesions and contribute directly to atherosclerosis development. In support of this notion, several epidemiological studies have found associations between inflammatory processes resulting from chronic infec-

tious diseases, i.e., of the respiratory system [5,6] or gums (periodontitis) [5,7], or from non-infectious autoimmune disorders, such as rheumatoid arthritis (RA) [8,9] and systemic lupus erythematosus (SLE) [10–12], and atherosclerosis and/or CVD. Furthermore, circulating levels of markers of inflammation, such as interleukin-6 (IL-6) and C-reactive protein (CRP), have been found to be predictors of atherosclerosis and cardiovascular events [13,14]. However, the contention that extravascular inflammation is itself a causative factor for accelerated atherosclerosis remains unproven. For example, chronic infections and autoimmune diseases are often associated with increased cardiovascular risk profiles [11,15,16]. Furthermore, some pathogens that are thought to promote atherosclerosis, such as *Chlamydia pneumoniae*, cytomegalovirus and other herpesviridae, can actually infect vascular cells [17], and autoimmune diseases are associated with vasculitis, arterial stiffness and vascular dysfunction [18,19]. It is important to determine if chronic inflammatory conditions in extravascular sites can actually cause or predispose to atherosclerotic cardiovascular disease especially in the presence of a proatherogenic dyslipidemia.

Mouse models constitute a powerful tool to study the pathogenesis of atherosclerosis, and can help to study the link between chronic inflammation and atherosclerosis [20]. In fact, recent reports have shown that different mouse strains with mutations that result in a lupus-susceptible immune system, a systemic disorder,

* Corresponding author. Address: Department of Medicine, Division of Diabetes, Endocrinology & Metabolism, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA. Fax: +1 713 798 8764.

E-mail address: lchan@bcm.edu (L. Chan).

¹ Present address: Cardiovascular Research Group, 408 Heritage Medical Research Centre, University of Alberta, Edmonton, Alta., Canada T5G 2S2.

² Present address: Center for Cardiovascular Sciences, Albany Medical College, Albany, NY 12208, USA.

can present with accelerated atherosclerosis [21–24]. If indeed extravascular inflammation is the underlying mechanism leading to accelerated atherosclerosis, patients with other forms of extravascular inflammation could also benefit from strict management of their cardiovascular risk factors. In this study, we assessed the effect of non-autoimmune chronic inflammation on atherosclerosis development in apoE^{−/−} mice, a widely used genetic animal model of atherosclerosis [25], by applying three well-characterized models of experimental inflammation: (1) croton oil-induced chronic skin lesions [26,27], (2) *Aspergillus fumigatus* antigen-induced allergic lung disease [28], and (3) *A. fumigatus* antigen-induced peritonitis.

Materials and methods

Animals. Female apoE^{−/−} mice (3–5 weeks age) were obtained from The Jackson Laboratory, housed in Baylor's Transgenic Mouse Facility, and given access to water and standard mouse chow *ad libitum*. Mice were separated into matched control and treatment groups based on serum cholesterol levels measured just before the beginning of treatments. Protocols for handling and treatment of animals were approved by the Institutional Animal Care and Use Committee at Baylor College of Medicine.

Croton oil-induced skin inflammation model. The lower backs of the mice were shaved using a scalpel under intraperitoneal (i.p.) anesthesia with avertin (2 mg/ml tribromoethanol [Aldrich] dissolved in *tert*-amyl alcohol, resuspended in 0.9% NaCl, 1:39, vol:vol), and a solution of 10% croton oil (Sigma) in acetone:olive oil (4:1, vol:vol) was applied to the exposed skin, resulting in focal ulcers and inflammation [26,27]. The skin ulcers healed completely with full return of hair within a month, after which time the treatment was repeated. Accordingly, croton oil treatments were performed beginning at 8 weeks of age and repeated every 4 weeks, i.e., week 12, 16, 20, 24, 28, and 32, until the mice were sacrificed by isoflurane inhalation for aortic lesion quantitation and skin histopathology at 34 weeks of age. After euthanasia the dorsal pelt was removed and fixed in 10% neutral buffered formaldehyde. The skin was trimmed to 2–4 mm wide strips cut parallel to the direction of hair growth. The trimmed skin specimens were paraffin embedded, sectioned at 4 μ m and stained with hematoxylin and eosin (H/E).

***Aspergillus fumigatus* antigen-induced allergic lung disease model.** The *A. fumigatus* preparation was made and administered intranasally (i.n.) to the treatment group as previously described [28], while the control group was left untreated. The time course of administration of *A. fumigatus* antigen was as follows: treatments at 10, 11, 12, and 14 weeks of age, followed by treatments every 4 weeks, i.e., at weeks 18, 22, 26, 30, 34, 38, and 42. Following completion of the treatment schedule, mice were sacrificed by overdose of pentobarbital. Bronchoalveolar lavage (BAL) fluid was collected from lungs by rinsing twice with 1 ml of PBS, then the lungs were removed and preserved in phosphate-buffered saline (PBS)/10% formalin. The heart and aorta were isolated for atherosclerosis measurements. Two hundred microliters of BAL fluid were placed in a cytospin apparatus and the cells were sedimented onto microscope slides, followed by Wright-Giemsa staining and differential cell counting [28]. Serum IgE levels were measured by ELISA as previously described [28]. Histological evaluation of formalin-fixed lung tissues was performed after H/E and Periodic Acid Schiff (PAS) staining of paraffin embedded tissue.

***Aspergillus fumigatus* antigen-induced peritonitis model.** Another set of mice was divided into plasma cholesterol matched controls and treatment groups in which the latter received *A. fumigatus* antigen by i.p. injection as described [29,30]. The i.p. treatments were performed at 10, 11, 12, and 14 weeks of age, followed by

treatments every 4 weeks, i.e., at weeks 18, 22, and 26. After the last treatment, the mice were sacrificed and aortas were harvested for lesion quantitation.

Plasma inflammation markers and cholesterol levels. Periodically, EDTA-blood was obtained by retro-orbital bleeding under avertin anesthetic to obtain leukocyte counts. Plasma levels of cytokines IL-6, tumor necrosis factor- α (TNF- α), and interleukin-1 β (IL-1 β) and acute phase protein serum amyloid A (SAA) were measured by ELISA kits (Biosource). Plasma cholesterol levels were measured by enzymatic kit (Sigma).

Aortic lesion quantitation (atherosclerosis measurements). Mice were sacrificed by overdose with anesthetic isoflurane or pentobarbital, as specified. The heart and abdominal aorta were removed and cleaned under a dissecting microscope. The aortas were opened longitudinally and pinned to cardboard, fixed overnight in PBS/10% formalin, and then stained with Oil Red O. *En face* lesion area quantitation using computer-assisted morphometry was performed as previously described [31].

Statistical analysis. Experimental groups were compared to controls or each other using Student's *t*-test or Mann–Whitney Rank Sum test. Values are reported as mean \pm standard deviation and a *P* value of equal or less than 0.05 was considered significant.

Results

Croton oil-induced chronic skin inflammation

Croton oil treatment of the shaved backs of the mice led to erythema and then ulceration of the area of application (approximately 2 cm² and not exceeding 2 cm in diameter) in the first few days after treatment. This was followed by a period of wound repair where the skin ulcer was red and scabbed or crusted. After about 1 week, the superficial crust and necrotic tissue peeled off, revealing intact skin by 10–14 days, and by 3 weeks, most of the fur had regrown. Histology revealed necrosis of epidermis and dermis, followed by ulceration with moderate to intense suppurative inflammation (Fig. 1A), then inflammation diminished as re-epithelialization (healing) progressed. In re-epithelialized or healed specimens there was epidermal and dermal thickening due to epidermal hyperplasia and dermal fibrosis, and there were scattered inflammatory cells in the dermis and subcutis. In older, multiply treated animals, there was xanthomatous change in the subcutis, sometimes with associated fat necrosis and foci of pyogranulomatous inflammation.

We measured various blood and plasma markers in order to further characterize the inflammatory process during croton oil treatment. One day after croton oil treatment, white blood cell (WBC) counts dropped, while by 4 days post-treatment and thereafter, the counts were slightly elevated (Fig. 1B, *top*). Levels of the pro-inflammatory cytokine IL-6 increased markedly, from undetectable to 1352 pg/ml, 1 day after croton oil treatment, but returned to near baseline within 4 days (Fig. 1B, *middle*). Coinciding with the changes in IL-6 level was a marked increase in the acute phase protein SAA, from a baseline level of 9.2–1287 μ g/ml 1 day post-treatment, decreasing to about 5–10 times above baseline from 4 to 11 days post-treatment (Fig. 1B, *bottom*). Neither TNF- α or IL-1 β levels were affected by croton oil treatment (data not shown). Shown measurements were taken at the last treatment interval before sacrifice of the animal for atherosclerotic lesion measurements. Measurements taken at an intermediate treatment time-point yielded similar results.

The mice were sacrificed at 34 weeks of age, two weeks after the final croton oil treatment. As shown in Table 1, there were no differences in plasma cholesterol and body weights between control and croton oil-treated mice. Lesions in apoE^{−/−} mice at this age consist




Fig. 1. (A) Histopathology of skin sections from control (left) and day 7 croton oil-treated (right) mice (40 \times) showing ulceration, inflammation, and necrosis in treated mice. (B) Leukocyte counts (top), IL-6 levels (middle), and SAA (bottom) levels from plasma of untreated control (solid symbol) and croton oil-treated (open symbols) mice at the indicated times after treatment.

mainly of intermediate lesions that present with macrophage infiltration, fibrosis and some necrotic cores [32]. Importantly, computer-assisted *en face* lesion quantitation revealed no difference in total lesional area between control and inflammation groups (control mean 10.19 mm² versus treated mean 10.21 mm², $P = 0.942$). Thus, repeated croton oil treatments (7 cycles) induced the formation of a chronic inflammatory skin lesion interspersed with transient healing, as well as a strong acute phase response, with pro-inflammatory cytokines detectable in the plasma and stimulation of hepatic production of acute phase proteins. However, this chronic dermatitis model did not influence the extent of atherosclerosis development in the aorta in apoE^{-/-} mice (see Fig. 2).

Aspergillus fumigatus allergic lung disease study

Next, we assessed the rate of atherosclerosis development in a model of asthma-like disease termed allergic lung disease. We in-

duced airway hyperreactivity by repeated i.n. delivery of *A. fumigatus* antigen (7 and 11 times over the course of 16 and 32 weeks, respectively). This is a well-characterized model in terms of local cytokine production both in BAL fluids and *in vitro* by lung cells, and inflammatory cellular infiltration into the lungs. Intranasal treatment of the mice with *A. fumigatus* antigen did not produce detectable alterations in plasma IL-6 levels or TNF- α levels 1 day (data not shown), and SAA levels were mildly increased from a baseline of 0.9 ± 0.8 to 65 ± 28 $\mu\text{g/ml}$. However, as previously described [28], plasma IgE, was markedly higher in animals receiving *A. fumigatus* by i.n. route (44.2 ± 7.7 $\mu\text{g/ml}$) versus untreated animals (2.9 ± 3.3 $\mu\text{g/ml}$). Histological analysis revealed marked lung inflammation characterized by increased eosinophil infiltration (detected by H/E staining) and the presence of enlarged mucous cells (seen by PAS staining) in *A. fumigatus* antigen treated animals (Fig. 3A). Finally, cytopsin analysis of BAL fluids showed a drastic increase in the proportion of eosinophils, as well as some

Table 1
Body weight and plasma cholesterol levels.

	Control group	Inflammation group
1. Chronic skin lesion study		
(6 weeks)		
Weight (g)	17.8 ± 0.8	18.1 ± 1.2
Cholesterol (mg/dl)	439 ± 84	439 ± 66
(33 weeks)		
Weight (g)	23.0 ± 0.7	22.5 ± 0.6
Cholesterol (mg/dl)	494 ± 69	523 ± 76
2. Allergic lung disease study		
(8 weeks)		
Weight (g)	17.9 ± 0.9	16.7 ± 0.8 ^a
Cholesterol (mg/dl)	432 ± 129	475 ± 147
(26 weeks)		
Weight (g)	22.4 ± 0.9	20.7 ± 1.3 ^a
Cholesterol (mg/dl)	452 ± 81	526 ± 86
(42 weeks)		
Weight (g)	ND	ND
Cholesterol (mg/dl)	454 ± 55	447 ± 77
3. Peritonitis study		
(8 weeks)		
Weight (g)	17.9 ± 0.9	17.4 ± 1.1
Cholesterol (mg/dl)	432 ± 129	454 ± 103
(26 weeks)		
Weight (g)	22.4 ± 0.9	21.5 ± 0.6 ^b
Cholesterol (mg/dl)	452 ± 81	442 ± 52

ND, not determined.

^a $P < 0.01$.

^b $P < 0.05$.

increase in neutrophils, in fluid from *A. fumigatus* antigen treated animals (Fig. 3B). Thus, this allergic lung disease model resulted in a strong inflammatory response in the lung, with only mild changes in the level of circulating pro-inflammatory cytokines or acute phase reactants.

The mice were sacrificed at 26 and 42 weeks of age and aortas were harvested for atherosclerosis measurements. Plasma choles-

terol levels did not differ between control and treated groups at either time-point. Body weight was decreased in the treatment group by 8% for the 26 week time-point, while no changes were observed at 42 weeks (Table 1). Again, similar to the chronic dermatitis model, despite the inflammatory changes observed in the lungs, at neither time-point was there any difference in total lesional area between controls and mice with *A. fumigatus* antigen-induced allergic lung disease (Fig. 4A).

Aspergillus fumigatus peritonitis study

At the same time that we investigated the allergic lung disease animals, we subjected another set of mice to repeated i.p. delivery of the same antigen in order to induce an inflammatory peritonitis. This treatment consisted of seven administrations of antigen over the course of 16 weeks, i.e., out to 26 weeks of age (see Materials and methods).

This method of antigen delivery is sufficient to induce marked increases in serum antigen-specific antibodies [29]. Intraperitoneal treatment of the mice with *A. fumigatus* antigen did not alter IL-6 or TNF- α levels in the plasma after 1 day (data not shown), but SAA levels were significantly increased above the baseline of 0.9 ± 0.8 – 111 ± 93 $\mu\text{g/ml}$ in the peritonitis model. Similar to the croton oil model, WBC counts dropped 1 day after antigen treatment, with gradual increase toward pretreatment levels (data not shown). There was no significant difference in serum IgE level in animals that received the i.p. antigen (3.5 ± 4.7 $\mu\text{g/ml}$) versus that in untreated animals (2.9 ± 3.3 $\mu\text{g/ml}$). Plasma cholesterol was similar in control and treated mice, while body weight decreased 4% in the chronic inflammation group (Table 1). Once more, quantitative morphometry revealed no difference in atherosclerotic lesion area between apoE^{-/-} mice afflicted by the induced peritonitis compared with that in untreated animals (Fig. 4B).




Fig. 2. Effect of inflammation by chronic skin lesion on atherosclerosis in apoE^{-/-} mice. Total aortic en face lesion area was determined in control and croton oil treated groups at 34 weeks of age.




Fig. 3. (A) Histological evaluation of lung inflammation following intranasal challenge with *A. fumigatus* allergen. Comparison of H/E stained lung sections from control (top left) and *A. fumigatus* antigen-challenged (top right) animals (20 \times), showing increased eosinophil infiltration in animals 1 day after the final allergen challenge. Comparison of PAS stained control (bottom left) and treated (bottom right) sections (20 \times) shows enlarged mucous cells in challenged animals. (B) Percentage of leukocytes in BAL fluid from control and *A. fumigatus* antigen-challenged groups. Proportions of eosinophils (EOS), monocytes (MON), neutrophils (NEU), and lymphocytes (LYM) were determined 1 day after the final challenge.

Discussion

In this study, we tested three different models of experimental recurrent or chronic inflammation on atherosclerosis development in apoE^{-/-} mice. The three models presented with local inflammation at different sites (skin, lungs and intraperitoneal), and different patterns of plasma markers of inflammation, with a robust increase in plasma IL-6 and SAA in croton oil-induced chronic skin inflammation, and more modest but significant increases in plasma SAA in both the *A. fumigatus*-induced allergic lung disease and peritonitis. However, none of the three models of inflammation were able to influence the rate of atherosclerosis development in apoE^{-/-} mice.

Epidemiological studies have shown a strong association between some inflammatory diseases, particularly autoimmune rheu-

matic diseases, and atherosclerosis [11,16]. Although a confounding factor in the epidemiological studies is that autoimmune rheumatic diseases are commonly associated with increases in “traditional” cardiovascular risk factors [11,16], the rates of cardiovascular events remain higher in patients with these diseases even after adjustment for baseline risk profiles [33,34]. Furthermore, several independent studies performed in different lupus mouse models, in which many of the “traditional” atherosclerotic risk factors can be controlled, support a connection between SLE and atherosclerosis [21–24]. We note that, like the current investigation, these studies were performed in dyslipidemic mice (LDL receptor deficiency for the first study, and apoE deficiency for the other two studies). We employed apoE^{-/-} mice as our model, but failed to detect any effect of three different non-autoimmune chronic inflammatory processes on atherosclerosis development. A possible explanation




Fig. 4. (A) Effect of inflammatory allergic lung disease on atherosclerosis in $\text{apoE}^{-/-}$. Lesion area was determined in control and *A. fumigatus* antigen-challenged groups at 26 (left) or 42 (right) weeks of age. (B) Effect of inflammatory peritonitis on atherosclerosis in $\text{apoE}^{-/-}$ mice. Total aortic *en face* lesion area was determined in control and *A. fumigatus* antigen-i.p. challenge groups at 26 weeks of age.

for this difference is that SLE and other systemic autoimmune inflammatory diseases affect multiple organs and tissues and are primarily associated with chronic vasculitis [16], which could be a major proatherogenic factor [35,36]. Furthermore, there is substantial overlap in the histopathology of vasculitis and atherosclerosis, itself a form of chronic vascular inflammation. Another factor noted in both SLE patients and mouse models is an increase in circulating anti-oxLDL and anti-cardiolipin antibodies that, together with the secretion of lupus-specific autoantibodies, could also contribute to modulate atherogenesis by mechanisms that could involve lipoprotein uptake by foam cells and/or immunomodulation at the lesion site [23,37]. Therefore, although autoimmune processes could share some common mechanisms of action with non-autoimmune chronic extravascular inflammation, such as the release of soluble mediators or the activation of leukocytes transiting through vessels perfusing the inflamed tissues, these may not be the main mechanisms responsible for the proatherogenic effects associated with the autoimmune disorders. We cannot rule out the possibility that other forms of chronic extravascular non-autoimmune inflammation may predispose to atherosclerosis in $\text{apoE}^{-/-}$ mice. However, the fact that none of three different models of chronic or recurrent inflammation is associated with accelerated atherosclerosis indicates that extravascular inflammation is unlikely to be a common risk factor for accelerated atherosclerotic cardiovascular diseases.

Acknowledgments

We thank Javier Martinez-Botas and Aksam Merched for assistance with some of the experimental procedures, and Leslie Wu for administrative assistance. This work was supported by a grant from the National Institutes of Health HL-51586 and by the Betty Rutherford Chair, St. Luke's Episcopal Hospital and Baylor College of Medicine, Houston, Texas (to Lawrence Chan). Antoni Paul was supported in part by a Scientist Development Grant from the American Heart association 0535118N.

References

- [1] W. Rosamond, K. Flegal, G. Friday, K. Furie, A. Go, K. Greenlund, N. Haase, M. Ho, V. Howard, B. Kissela, S. Kittner, D. Lloyd-Jones, M. McDermott, J. Meigs, C. Moy, G. Nichol, C.J. O'Donnell, V. Roger, J. Rumsfeld, P. Sorlie, J. Steinberger, T. Thom, S. Wasserthiel-Smoller, Y. Hong, for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Heart disease and stroke statistics – 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, *Circulation* 115 (2007) e69–e171.
- [2] J.A. Berliner, M. Navab, A.M. Fogelman, J.S. Frank, L.L. Demer, P.A. Edwards, A.D. Watson, A.J. Lusis, Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics, *Circulation* 91 (1995) 2488–2496.
- [3] J.T. Willerson, P.M. Ridker, Inflammation as a cardiovascular risk factor, *Circulation* 109 (2004) II2–II10.
- [4] R. Ross, Atherosclerosis – an inflammatory disease, *N. Engl. J. Med.* 340 (1999) 115–126.

- [5] S. Kiechl, G. Egger, M. Mayr, C.J. Wiedermann, E. Bonora, F. Oberhollenzer, M. Muggeo, Q. Xu, G. Wick, W. Poewe, J. Willeit, Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study, *Circulation* 103 (2001) 1064–1070.
- [6] C.R. Meier, S.S. Jick, L.E. Derby, C. Vasilakis, H. Jick, Acute respiratory-tract infections and risk of first-time acute myocardial infarction, *Lancet* 351 (1998) 1467–1471.
- [7] D.W. Paquette, The periodontal infection-systemic disease link: a review of the truth or myth, *J. Int. Acad. Periodontol.* 4 (2002) 101–109.
- [8] S.M. Naz, D.P. Symmons, Mortality in established rheumatoid arthritis, *Best Pract. Res. Clin. Rheumatol.* 21 (2007) 871–883.
- [9] D.H. Solomon, N.J. Goodson, J.N. Katz, M.E. Weinblatt, J. Avorn, S. Setoguchi, C. Canning, S. Schneeweiss, Patterns of cardiovascular risk in rheumatoid arthritis, *Ann. Rheum. Dis.* 65 (2006) 1608–1612.
- [10] A.H. Kao, J.M. Sabatine, S. Manzi, Update on vascular disease in systemic lupus erythematosus, *Curr. Opin. Rheumatol.* 15 (2003) 519–527.
- [11] B.H. Hahn, J. Grossman, W. Chen, M. McMahon, The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia, *J. Autoimmun.* 28 (2007) 69–75.
- [12] I.N. Bruce, 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus, *Rheumatology (Oxford)* 44 (2005) 1492–1502.
- [13] P.M. Ridker, N. Rifai, M.J. Stampfer, C.H. Hennekens, Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men, *Circulation* 101 (2000) 1767–1772.
- [14] P.M. Ridker, N. Rifai, L. Rose, J.E. Buring, N.R. Cook, Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events, *N. Engl. J. Med.* 347 (2002) 1557–1565.
- [15] A. Steptoe, A. Shamaei-Tousi, A. Gylfe, B. Henderson, S. Bergstrom, M. Marmot, Socioeconomic status, pathogen burden and cardiovascular disease risk, *Heart* 93 (2007) 1567–1570.
- [16] S. Haque, H. Mirjafari, I.N. Bruce, Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus, *Curr. Opin. Lipidol.* 19 (2008) 338–343.
- [17] J.B. Muhlestein, J.L. Anderson, Infectious serology and atherosclerosis: how burdensome is the risk?, *Circulation* 107 (2003) 220–222.
- [18] M.J. Roman, R.B. Devereux, J.E. Schwartz, M.D. Lockshin, S.A. Paget, A. Davis, M.K. Crow, L. Sammaritano, D.M. Levine, B.A. Shankar, E. Moeller, J.E. Salmon, Arterial stiffness in chronic inflammatory diseases, *Hypertension* 46 (2005) 194–199.
- [19] D. Datta, W.R. Ferrell, R.D. Sturrock, S.T. Jadhav, N. Sattar, Inflammatory suppression rapidly attenuates microvascular dysfunction in rheumatoid arthritis, *Atherosclerosis* 192 (2007) 391–395.
- [20] J.L. Breslow, Mouse models of atherosclerosis, *Science* 272 (1996) 685–688.
- [21] T. Aprahamian, I. Rifkin, R. Bonegio, B. Hugel, J.M. Freyssonet, K. Sato, J.J. Castellot Jr., K. Walsh, Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease, *J. Exp. Med.* 199 (2004) 1121–1131.
- [22] A.K. Stanic, C.M. Stein, A.C. Morgan, S. Fazio, M.F. Linton, E.K. Wakeland, N.J. Olsen, A.S. Major, Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus, *Proc. Natl. Acad. Sci. USA* 103 (2006) 7018–7023.
- [23] X. Feng, H. Li, A.A. Rumbin, X. Wang, C.A. La, K. Brechtelsbauer, L.W. Castellani, J.L. Witztum, A.J. Lusis, B.P. Tsao, ApoE^{-/-}Fas^{-/-} C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia, *J. Lipid Res.* 48 (2007) 794–805.
- [24] Z. Ma, A. Choudhury, S.A. Kang, M. Monestier, P.L. Cohen, R.A. Eisenberg, Accelerated atherosclerosis in ApoE deficient lupus mouse models, *Clin. Immunol.* 127 (2008) 168–175.
- [25] K.S. Meir, E. Leitersdorf, Atherosclerosis in the apolipoprotein E-deficient mouse: a decade of progress, *Arterioscler. Thromb. Vasc. Biol.* 24 (2004) 1006–1014.
- [26] D.J. Berg, M.W. Leach, R. Kuhn, K. Rajewsky, W. Muller, N.J. Davidson, D. Rennick, Interleukin 10 but not interleukin 4 is a natural suppressant of cutaneous inflammatory responses, *J. Exp. Med.* 182 (1995) 99–108.
- [27] J.P. Mizgerd, D.C. Bullard, M.J. Hicks, A.L. Beaudet, C.M. Doerschuk, Chronic inflammatory disease alters adhesion molecule requirements for acute neutrophil emigration in mouse skin, *J. Immunol.* 162 (1999) 5444–5448.
- [28] G. Grunig, D.B. Corry, M.W. Leach, B.W. Seymour, V.P. Kurup, D.M. Rennick, Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis, *J. Exp. Med.* 185 (1997) 1089–1099.
- [29] D.B. Corry, G. Grunig, H. Hadeiba, V.P. Kurup, M.L. Warnock, D. Sheppard, D.M. Rennick, R.M. Locksley, Requirements for allergen-induced airway hyperactivity in T and B cell-deficient mice, *Mol. Med.* 4 (1998) 344–355.
- [30] P.S. Murali, A. Kumar, H. Choi, N.K. Banasal, J.N. Fink, V.P. Kurup, *Aspergillus fumigatus* antigen induced eosinophilia in mice is abrogated by anti-IL-5 antibody, *J. Leukoc. Biol.* 53 (1993) 264–267.
- [31] N.V. Guevara, H.S. Kim, E.I. Antonova, L. Chan, The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo, *Nat. Med.* 5 (1999) 335–339.
- [32] Y. Nakashima, A.S. Plump, E.W. Raines, J.L. Breslow, R. Ross, ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree, *Arterioscler. Thromb.* 14 (1994) 133–140.
- [33] J.M. Esdaile, M. Abrahamowicz, T. Grodzicky, Y. Li, C. Panaritis, B.R. du, R. Cote, S.A. Grover, P.R. Fortin, A.E. Clarke, J.L. Senecal, Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus, *Arthritis Rheum.* 44 (2001) 2331–2337.
- [34] R. del I, K. Williams, M.P. Stern, G.L. Freeman, A. Escalante, High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors, *Arthritis Rheum.* 44 (2001) 2737–2745.
- [35] P.A. Bacon, R.J. Stevens, D.M. Carruthers, S.P. Young, G.D. Kitas, Accelerated atherogenesis in autoimmune rheumatic diseases, *Autoimmun. Rev.* 1 (2002) 338–347.
- [36] L. Guillevin, T. Dorner, Vasculitis: mechanisms involved and clinical manifestations, *Arthritis Res. Ther.* 9 (Suppl. 2) (2007) S9.
- [37] J. Frostegard, E. Svenungsson, R. Wu, I. Gunnarsson, I.E. Lundberg, L. Klareskog, S. Horkko, J.L. Witztum, Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations, *Arthritis Rheum.* 52 (2005) 192–200.